No Data
Improved Earnings Required Before China National Accord Medicines Corporation Ltd. (SZSE:000028) Shares Find Their Feet
Sinopharm is consistent: 2024 performance forecast
China National Accord Medicines Corporation (000028.SZ): The net income for 2024 is预计将下降52.48%-64.92%.
On January 17, Gelonghui reported that China National Accord Medicines Corporation (000028.SZ) announced its performance forecast for the year 2024, expecting a Net income attributable to shareholders of the listed company to be between 0.561 billion yuan and 0.76 billion yuan, a decrease of 52.48%-64.92% compared to the same period last year; Net income after deducting non-recurring gains and losses is expected to be between 0.497 billion yuan and 0.696 billion yuan, a decrease of 54.59%-67.58% compared to the same period last year; the basic EPS is estimated to be between 1.01 yuan/share and 1.37 yuan/share. During the reporting period, factors such as outpatient planning and other medical reform policies profoundly influenced the behavior of end consumers in the pharmaceutical retail sector.
Express News | China National Accord Medicines Sees 2024 Net Profit Down 52.5%-64.9% Y/Y
Earnings Growth of 0.7% Over 5 Years Hasn't Been Enough to Translate Into Positive Returns for China National Accord Medicines (SZSE:000028) Shareholders
China National Accord Medicines Corporation (000028.SZ): Director and General Manager Lin Zhaoxiong resigns.
On November 25th, Gelunhui announced that the Board of Directors of China National Accord Medicines Corporation (000028.SZ) received the resignation application submitted by Mr. Lin Zhaoxiong, the director and general manager of the company, on November 22, 2024. Due to work arrangement adjustments, Mr. Lin Zhaoxiong applied to resign from the positions of director, member of the Board of Directors Strategic Committee, and general manager of the company. After resigning, he will not hold any other positions in the company. As of the date of this announcement, Mr. Lin Zhaoxiong does not hold any stocks of the company. The Board of Directors has authorized Mr. Li Jinxiong, the deputy secretary of the company's party committee and deputy general manager, to lead the operation management work during the vacancy of the general manager position, with the authorization period starting from this board meeting.
Investors Aren't Buying China National Accord Medicines Corporation Ltd.'s (SZSE:000028) Earnings
